Dr. Yawei Hua 花亚伟
Chief Physician
Department of General Surgery, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical and multidisciplinary treatment of cardia, gastrointestinal, liver, pancreatic cancers, and malignant melanoma. Specializes in standard and extended radical gastrectomy, intraperitoneal chemotherapy, minimally invasive surgery, and molecular targeted therapy.
Dr. Hua is Deputy Director and Chief Physician at Henan Cancer Hospital with a Master of Medicine. Trained in Italy in 2002, Dr. Hua focuses on clinical and research work in general surgical oncology. Expertise includes intraoperative 125I seed implantation for advanced gastric cancer and perioperative intraperitoneal hyperthermic perfusion for gastrointestinal tumors.
Professional roles
- Member, International Gastric Cancer Association (IGCA)
- Member, Oncology Branch, Chinese Medical Association
- Standing Committee Member, Minimally Invasive Surgery Professional Committee, China Anti-Cancer Association
- Chair, Gastric Cancer Professional Committee, Henan Anti-Cancer Association
Name order: in Chinese the family name comes first (Hua Yawei). Papers usually list the name as Yawei Hua or Hua Y.
Selected publications
18 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Gastrointest Surg, 2023 (senior author): Diagnostic and Prognostic Value of CPZ in Patients with Gastric Cancer by Integrated Analysis. PubMed 36897519
- Updates Surg, 2023 (senior author): Is single tract jejunal interposition better than double tract reconstruction after proximal gastrectomy?. PubMed 36208365
- Asian J Surg, 2022 (senior author): Adenosquamous carcinoma of sigmoid colon in an adolescent: A case report and literature review. PubMed 35183422
- Carcinogenesis, 2021 (senior author): LncRNA MCF2L-AS1 aggravates proliferation, invasion and glycolysis of colorectal cancer cells via the crosstalk with miR-874-3p/FOXM1 signaling axis. PubMed 32860508
- Drug Deliv, 2020 (senior author): Enhancing the chemotherapy effect of Apatinib on gastric cancer by co-treating with salidroside to reprogram the tumor hypoxia micro-environment and induce cell apoptosis. PubMed 32397840
- Exp Ther Med, 2018 (senior author): MicroRNA-218 enhances gastric cancer cell cisplatin sensitivity by targeting survivin. PubMed 30542435
- Oncol Rep, 2016 (senior author): Upregulation of microRNA-34a enhances the DDP sensitivity of gastric cancer cells by modulating proliferation and apoptosis via targeting MET. PubMed 27513895
- World J Surg Oncol, 2014 (senior author): Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. PubMed 24758484
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion